✦ LIBER ✦

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study

✍ Scribed by Yazici, Y.; Curtis, J. R.; Ince, A.; Baraf, H.; Malamet, R. L.; Teng, L. L.; Kavanaugh, A.

Book ID: 111950202
Publisher: BMJ Publishing Group
Year: 2011
Tongue: English
Weight: 301 KB
Volume: 71
Category: Article
ISSN: 0003-4967
DOI: 10.1136/ard.2010.148700

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Indirect Comparison of Tocilizumab and O

Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

✍ Gert J.D. Bergman; Marc C. Hochberg; Maarten Boers; Neil Wintfeld; Adrian Kielho 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 595 KB

Interleukin-6 receptor inhibition with t

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

✍ Mark C. Genovese; James D. McKay; Evgeny L. Nasonov; Eduardo F. Mysler; Nilzio A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

Indirect comparisons of the efficacy of

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

✍ Salliot, C.; Finckh, A.; Katchamart, W.; Lu, Y.; Sun, Y.; Bombardier, C.; Keysto 📂 Article 📅 2010 🏛 BMJ Publishing Group 🌐 English ⚖ 299 KB

Phase IIb dose-ranging study of the oral

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

✍ Roy Fleischmann; Maurizio Cutolo; Mark C. Genovese; Eun Bong Lee; Keith S. Kanik 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 4 views

PMS33 Cost-Efficacy Analysis of Biologic

PMS33 Cost-Efficacy Analysis of Biologic Drugs in Combination With DMARDs in Patients With Active Rheumatoid Arthritis and Inadequate Response to Traditional DMARDs in Portugal – A Simplified Approach

✍ A. Cafe; I. Monteiro; J.F. Loff; R. Encarnação 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Ofatumumab, a human anti-CD20 monoclonal

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

✍ Mikkel Østergaard; Bo Baslund; William Rigby; Bernadette Rojkovich; Christian Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 2 views